<a href="https://laohu8.com/S/PMCB">PharmaCyte Biotech</a> Reports No Revenue and Reduced Operating Expenses for Fiscal Year 2025
PharmaCyte Biotech Inc., a biotechnology company focused on cellular therapies for cancer, released its annual report for the fiscal year ending April 30, 2025. The company reported no revenues for the fiscal years 2025 and 2024. Operating expenses totaled $4.38 million for the year ended April 30, 2025, marking a decrease of $4.14 million compared to the previous year. This reduction was primarily due to lower compensation, director fees, and legal and professional expenses, although research and development (R&D) expenses increased by $30,985 to $438,416. This rise in R&D spending was attributed to a new agreement with consultants to conduct further research into pancreatic cancer treatment. The company highlighted its efforts to prepare for a planned clinical trial in locally advanced pancreatic cancer (LAPC). Looking ahead, PharmaCyte Biotech stated that its current cash reserves are expected to cover operating expenses for at least the next 12 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-005821), on August 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.